alexa Study For Establishment Of 1st National Reference Standard For Cell-derived Japanese Encephalitis Vaccine (Beijing Strain)
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

16th Euro Global Summit and Expo on Vaccines & Vaccination
June 19-21, 2017 Paris, France

Ji Young Hong, Sangil Choi, Sunbo Shim and Sangja Ban
National Institute of Food and Drug Safety Evaluation, South Korea
Posters & Accepted Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560-C1-058
Japanese encephalitis virus (JEV) is a mosquito-born flavivirus that causes public health problems in Asian countries. Until quite recently, the primary JE vaccine in use internationally has been the mouse brains JE vaccine, which is now commonly replaced by cell culture-based vaccines. The Vero cell derived JE vaccines have been licensed for routine use in Korea, 2013. In Korea, we have the system of National Lot Release. Unlike chemical drugs, biologics such as viral vaccine, bacterial vaccine and blood products are produced using organism-origin materials, so it is difficult to maintain consistency and safety throughout the manufacturing processes. Also, the reference standard is indispensable for the consistent potency management of viral vaccine. The candidate 1st National Reference Standard was manufactured in GMP facility and all quality test results including potency test meet the acceptance criteria. In this study, the candidate 1st National Reference Standard was manufactured in GMP facility and all quality test results including potency test meet the acceptance criteria. To determine relative potency of candidate material, a collaborative study involving 4 participants including both NCL and manufacturers was carried out potency test using plaque reduction neutralization test (PRNT). Therefore, it plans to determine and establish the quality of the candidate of the 1st National Reference Standard based on a long-term stability test data and collaborative results and use it to establish the quality of the vaccine.

Ji Young Hong has completed her Master’s degree in Molecular-Biology from Korea University. She has worked in the Division of Enteric Hepatitis Virus, National Institute of Health for about 5 years. She is working on Vaccines Division, National Institute of Food and Drug Safety Evaluation since 2009.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version